All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
The clinical development of B-cell maturation antigen (BCMA)-CD3 directed bispecific antibody therapies represents an important advancement in the treatment of multiple myeloma (MM), with their role in clinical practice continuing to evolve.
The Multiple Myeloma Hub spoke with Hang Quach, Alexander Lesokhin, and Sagar Lonial to gain their expert perspectives on how these agents are being used in real-world practice, combination strategies under investigation, and future applications for BCMA-directed bispecifics in the treatment of MM and other plasma cell dyscrasias.
.webp)
The Multiple Myeloma Hub was pleased to speak with Hang Quach. We asked, How are BCMA-directed bispecific antibodies currently utilized in real-world practice for multiple myeloma?
.webp)
The Multiple Myeloma Hub spoke with Alexander Lesokhin, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for multiple myeloma?
.webp)
The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What might be the future applications for BCMA-directed bispecific antibodies in multiple myeloma and other plasma cell dyscrasias?
This educational resource is independently supported by Pfizer. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following reflects your thoughts about the possibility of implementing a novel drug delivery device at your clinical practice site?
Sagar Lonial
Hang Quach